Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

Abstract

During February 12-August 24, 2001, a total of 21 cases of liver injury associated with a 2-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent tuberculosis infection (LTBI) was reported to CDC. These 21 cases are in addition to two previously reported RIF-PZA-associated cases. Cases of liver injury have occurred each year since 1999. CDC also received reports of 10 cases associated with other LTBI treatment regimens; however, risk for liver injury cannot be compared among treatment regimens in part because the number of patients treated for LTBI with each treatment regimen is unknown. This report provides preliminary information about the 21 cases associated with RIF-PZA and the revised recommendations on selecting appropriate LTBI therapy for patients and monitoring the use of RIF-PZA to treat LTBI. In most instances, the 9-month isoniazid (INH) regimen is preferred for the treatment of patients with LTBI. RIF-PZA may be used in selected cases and requires more intensive clinical and laboratory monitoring than previously recommended.

• Authors: Centers for Disease Control and Prevention (CDC)
• Journal: MMWR. Morbidity and mortality weekly report (MMWR Morb Mortal Wkly Rep) Vol. 50 Issue 34 Pg. 733-5 (Aug 31 2001) ISSN: 0149-2195 [Print] United States
• PMID: 11787580 (Publication Type: Journal Article)

Chemical References

• Antitubercular Agents
• Pyrazinamide
• Rifampin

Topics

• Adult
• Aged
• Antitubercular Agents (adverse effects, therapeutic use)
• Chemical and Drug Induced Liver Injury (etiology, mortality)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Practice Guidelines as Topic
• Pyrazinamide (adverse effects, therapeutic use)
• Rifampin (adverse effects, therapeutic use)
• Tuberculosis (drug therapy)